Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HRH2 | P25021 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11106320 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11010882 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| Lavoltidine SCHEMBL30095469 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10751306 | 0.97 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| Lavoltidine SCHEMBL633369 | 0.94 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| Acetic Acid SCHEMBL11011722 | 0.93 | HRH2 (0.52) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4607091 | 0.93 | SMN1; SMN2 (0.54) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11100251 | 0.92 | TP53 (0.47) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11068165 | 0.91 | SMN1; SMN2 (0.52) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL11483567 | 0.91 | TSHR (0.45) | SMN1; SMN2TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1050 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| US-20230349922-A1 | H2 Blockers Targeting Liver Macrophages for the Prevention and Treatment of Liver Disease and Cancer | UNIVERSITÉ DE STRASBOURG (FR) | 2023-11-02 | — | — | US | claimed |
| EP-4196793-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | Université de Strasbourg (FR) | 2023-06-21 | — | — | EP | claimed |
| US-20230129326-A1 | METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19 | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-04-27 | — | — | US | claimed |
| EP-4132967-A2 | METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19 | University of Florida Research Foundation, Incorporated (US) | 2023-02-15 | — | — | EP | claimed |
| WO-2022034121-A1 | H2 BLOCKERS TARGETING LIVER MACROPHAGES FOR THE PREVENTION AND TREATMENT OF LIVER DISEASE AND CANCER | UNIVERSITÉ DE STRASBOURG (FR) | 2022-02-17 | — | — | WO | claimed |
| US-20210353656-A1 | COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND HISTAMINE H2 RECEPTOR ANTAGONISTS FOR VIRAL INFECTIONS | NUVAMID SA (CH) | 2021-11-18 | — | — | US | claimed |
| WO-2020032883-A2 | SYNERGISTIC EFFECTS OF A NOVEL KETOPROFEN FORMULATION INCLUDING A GASTRO PROTECTIVE AGENT | PISAK MEHMET NEVZAT (TR) | 2020-02-13 | — | — | WO | claimed |
| WO-1996016640-A1 | ORAL COMPOSITIONS OF H2-ANTAGONISTS | APPLIED ANALYTICAL INDUSTRIES, INC. (US) | 1996-06-06 | — | — | WO | claimed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | claimed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | claimed |
| EP-0367484-B1 | Carboxylic acid derivates | GLAXO GROUP LTD (GB) | 1994-02-16 | — | — | EP | claimed |
| WO-1993020815-A1 | USE OF H-2 ANTAGONISTS FOR TREATMENT OF GINGIVITIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-10-28 | — | — | WO | claimed |
| EP-0275669-B1 | USE OF HETEROCYCLIC DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS | GLAXO GROUP LIMITED (GB) | 1992-09-30 | — | — | EP | claimed |
| EP-0367484-A1 | Carboxylic acid derivates | GLAXO GROUP LIMITED (GB) | 1990-05-09 | — | — | EP | claimed |
| EP-0275669-A1 | Use of heterocyclic derivatives for the manufacture of medicaments | GLAXO GROUP LIMITED (GB) | 1988-07-27 | — | — | EP | claimed |
| EP-0016565-B1 | 1,2,4-TRIAZOLE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 1984-05-23 | — | — | EP | claimed |
| EP-0016565-A1 | 1,2,4-Triazole derivatives, processes for their production and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1980-10-01 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353656-A1 | COMBINATION OF NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND HISTAMINE H2 RECEPTOR ANTAGONISTS FOR VIRAL INFECTIONS | HRH2, HRH4, HRH3 | SMN1; SMN2 3648/4885TP53 4137/4885CYP1A2 1909/4885 |
| US-20230129326-A1 | METHODS TO PREVENT SARS-COV-2 INFECTION AND TREAT COVID-19 | ACE2, ACE, TMPRSS2 | SMN1; SMN2 3431/4885TP53 1472/4885CYP1A2 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.